{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:20:21Z","timestamp":1790630421434,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"22","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,6,19]]},"DOI":"10.1038\/s41388-026-03795-9","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:20:36Z","timestamp":1776702036000},"page":"2137-2154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-2208","authenticated-orcid":false,"given":"Chushu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8662-2272","authenticated-orcid":false,"given":"Shouyan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minxian","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-9479","authenticated-orcid":false,"given":"Kun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-6699","authenticated-orcid":false,"given":"Fenglin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"3795_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","volume":"9","author":"P Wee","year":"2017","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9:52.","journal-title":"Cancers"},{"key":"3795_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3795_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354.","journal-title":"Semin Cancer Biol"},{"key":"3795_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrd1445","volume":"3","author":"J Graham","year":"2004","unstructured":"Graham J, Muhsin M, Kirkpatrick P. Cetuximab. Nat Rev Drug Discov. 2004;3:549\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"3795_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","volume":"5","author":"YH Xie","year":"2020","unstructured":"Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:22.","journal-title":"Signal Transduct Target Ther"},{"key":"3795_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","volume":"15","author":"MB Ryan","year":"2018","unstructured":"Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018;15:709\u201320.","journal-title":"Nat Rev Clin Oncol"},{"key":"3795_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.aam7622","volume":"355","author":"B Papke","year":"2017","unstructured":"Papke B, Der CJ. Drugging RAS: know the enemy. Science. 2017;355:1158\u201363.","journal-title":"Science"},{"key":"3795_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227\u201335.","journal-title":"Cancer Discov"},{"key":"3795_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;17:676\u201391.","journal-title":"Nat Rev Cancer"},{"key":"3795_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","volume":"10","author":"Y Song","year":"2023","unstructured":"Song Y, Bi Z, Liu Y, Qin F, Wei Y, Wei X. Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: current status in clinical trials. Genes Dis. 2023;10:76\u201388.","journal-title":"Genes Dis"},{"key":"3795_CR11","doi-asserted-by":"crossref","unstructured":"Cheng Y, Tian H. Current development status of MEK inhibitors. Molecules 2017; 22:1551.","DOI":"10.3390\/molecules22101551"},{"key":"3795_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","volume":"15","author":"CJ Caunt","year":"2015","unstructured":"Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer. 2015;15:577\u201392.","journal-title":"Nat Rev Cancer"},{"key":"3795_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103811","volume":"99","author":"A Ayati","year":"2020","unstructured":"Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020;99:103811.","journal-title":"Bioorg Chem"},{"key":"3795_CR14","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015;5:358\u201367.","journal-title":"Cancer Discov"},{"key":"3795_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795\u2013801.","journal-title":"Nat Med"},{"key":"3795_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726\u201336.","journal-title":"N Engl J Med"},{"key":"3795_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov. 2018;8:428\u201343.","journal-title":"Cancer Discov"},{"key":"3795_CR18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 2019;9:329\u201341.","journal-title":"Cancer Discov"},{"key":"3795_CR19","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/1535-7163.MCT-17-0456","volume":"16","author":"UA Germann","year":"2017","unstructured":"Germann UA, Furey BF, Markland W, Hoover RR, Aronov AM, Roix JJ, et al. Targeting the MAPK signaling pathway in cancer: promising preclinical activity with the novel selective ERK1\/2 inhibitor BVD-523 (Ulixertinib). Mol Cancer Ther. 2017;16:2351\u201363.","journal-title":"Mol Cancer Ther"},{"key":"3795_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","volume":"8","author":"RJ Sullivan","year":"2018","unstructured":"Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1\/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase i dose-escalation and expansion study. Cancer Discov. 2018;8:184\u201395.","journal-title":"Cancer Discov"},{"key":"3795_CR21","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","volume":"3","author":"EJ Morris","year":"2013","unstructured":"Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013;3:742\u201350.","journal-title":"Cancer Discov"},{"key":"3795_CR22","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1021\/acs.jmedchem.6b00389","volume":"59","author":"JF Blake","year":"2016","unstructured":"Blake JF, Burkard M, Chan J, Chen H, Chou KJ, Diaz D, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1\/2 (ERK1\/2) inhibitor in early clinical development. J Med Chem. 2016;59:5650\u201360.","journal-title":"J Med Chem"},{"key":"3795_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1158\/1535-7163.MCT-19-0183","volume":"19","author":"SV Bhagwat","year":"2020","unstructured":"Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, et al. ERK inhibitor LY3214996 targets ERK pathway-driven cancers: a therapeutic approach toward precision medicine. Mol Cancer Ther. 2020;19:325\u201336.","journal-title":"Mol Cancer Ther"},{"key":"3795_CR24","doi-asserted-by":"publisher","first-page":"13561","DOI":"10.1021\/acs.jmedchem.2c01244","volume":"65","author":"L Fu","year":"2022","unstructured":"Fu L, Chen S, He G, Chen Y, Liu B. Targeting extracellular signal-regulated protein kinase 1\/2 (ERK1\/2) in cancer: an update on pharmacological small-molecule inhibitors. J Med Chem. 2022;65:13561\u201373.","journal-title":"J Med Chem"},{"key":"3795_CR25","doi-asserted-by":"crossref","unstructured":"Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, et al. Development of MK-8353, an orally administered ERK1\/2 inhibitor, in patients with advanced solid tumors. JCI Insight 2018; 3:e92352.","DOI":"10.1172\/jci.insight.92352"},{"key":"3795_CR26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1158\/1535-7163.MCT-15-0172","volume":"15","author":"S Jha","year":"2016","unstructured":"Jha S, Morris EJ, Hruza A, Mansueto MS, Schroeder GK, Arbanas J, et al. Dissecting therapeutic resistance to ERK inhibition. Mol Cancer Ther. 2016;15:548\u201359.","journal-title":"Mol Cancer Ther"},{"key":"3795_CR27","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-17-3674","volume":"24","author":"BS Jaiswal","year":"2018","unstructured":"Jaiswal BS, Durinck S, Stawiski EW, Yin J, Wang W, Lin E, et al. ERK mutations and amplification confer resistance to ERK-inhibitor therapy. Clin Cancer Res. 2018;24:4044\u201355.","journal-title":"Clin Cancer Res"},{"key":"3795_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000477904","volume":"4","author":"C Li","year":"2017","unstructured":"Li C, Wang H, Yao H, Fang JY, Xu J. Scaffold proteins in gastrointestinal tumors as a shortcut to oncoprotein activation. Gastrointest Tumors. 2017;4:1\u201310.","journal-title":"Gastrointest Tumors"},{"key":"3795_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fcell.2016.00049","volume":"4","author":"B Casar","year":"2016","unstructured":"Casar B, Crespo P. ERK signals: scaffolding scaffolds? Front Cell Dev Biol. 2016;4:49.","journal-title":"Front Cell Dev Biol"},{"key":"3795_CR30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nm.3165","volume":"19","author":"KL Jameson","year":"2013","unstructured":"Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, et al. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med. 2013;19:626\u201330.","journal-title":"Nat Med"},{"key":"3795_CR31","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.1074\/jbc.M116.767087","volume":"292","author":"AJ Bardwell","year":"2017","unstructured":"Bardwell AJ, Lagunes L, Zebarjedi R, Bardwell L. The WW domain of the scaffolding protein IQGAP1 is neither necessary nor sufficient for binding to the MAPKs ERK1 and ERK2. J Biol Chem. 2017;292:8750\u201361.","journal-title":"J Biol Chem"},{"key":"3795_CR32","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1093\/jnci\/djt271","volume":"105","author":"X Kong","year":"2013","unstructured":"Kong X, Qian J, Chen LS, Wang YC, Wang JL, Chen H, et al. Synbindin in extracellular signal-regulated protein kinase spatial regulation and gastric cancer aggressiveness. J Natl Cancer Inst. 2013;105:1738\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"3795_CR33","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1534-5807(02)00364-7","volume":"3","author":"D Teis","year":"2002","unstructured":"Teis D, Wunderlich W, Huber LA. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. Dev Cell. 2002;3:803\u201314.","journal-title":"Dev Cell"},{"key":"3795_CR34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1097-2765(03)00406-4","volume":"12","author":"S Ishibe","year":"2003","unstructured":"Ishibe S, Joly D, Zhu X, Cantley LG. Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell. 2003;12:1275\u201385.","journal-title":"Mol Cell"},{"key":"3795_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.devcel.2004.05.019","volume":"7","author":"S Torii","year":"2004","unstructured":"Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. Sef is a spatial regulator for Ras\/MAP kinase signaling. Dev Cell. 2004;7:33\u201344.","journal-title":"Dev Cell"},{"key":"3795_CR36","doi-asserted-by":"publisher","first-page":"E2934","DOI":"10.1073\/pnas.1301985110","volume":"110","author":"V Reiterer","year":"2013","unstructured":"Reiterer V, Fey D, Kolch W, Kholodenko BN, Farhan H. Pseudophosphatase STYX modulates cell-fate decisions and cell migration by spatiotemporal regulation of ERK1\/2. Proc Natl Acad Sci USA. 2013;110:E2934\u20132943.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3795_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1128\/MCB.00800-07","volume":"28","author":"R Lefloch","year":"2008","unstructured":"Lefloch R, Pouyss\u00e9gur J, Lenormand P. Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol. 2008;28:511\u201327.","journal-title":"Mol Cell Biol"},{"key":"3795_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fcell.2016.00053","volume":"4","author":"R Busc\u00e0","year":"2016","unstructured":"Busc\u00e0 R, Pouyss\u00e9gur J, Lenormand P. ERK1 and ERK2 map kinases: specific roles or functional redundancy? Front Cell Dev Biol. 2016;4:53.","journal-title":"Front Cell Dev Biol"},{"key":"3795_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12862-015-0450-x","volume":"15","author":"R Busc\u00e0","year":"2015","unstructured":"Busc\u00e0 R, Christen R, Lovern M, Clifford AM, Yue JX, Goss GG, et al. ERK1 and ERK2 present functional redundancy in tetrapods despite the higher evolution rate of ERK1. BMC Evol Biol. 2015;15:179.","journal-title":"BMC Evol Biol"},{"key":"3795_CR40","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.celrep.2015.07.011","volume":"12","author":"C Fr\u00e9min","year":"2015","unstructured":"Fr\u00e9min C, Saba-El-Leil MK, L\u00e9vesque K, Ang SL, Meloche S. Functional redundancy of ERK1 and ERK2 MAP kinases during development. Cell Rep. 2015;12:913\u201321.","journal-title":"Cell Rep"},{"key":"3795_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189105","volume":"1879","author":"S Patra","year":"2024","unstructured":"Patra S, Roy PK, Dey A, Mandal M. Impact of HMGB1 on cancer development and therapeutic insights focused on CNS malignancy. Biochim Biophys Acta Rev Cancer. 2024;1879:189105.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3795_CR42","first-page":"1531","volume":"26","author":"MK Petri","year":"2011","unstructured":"Petri MK, Koch P, Stenzinger A, Kuchelmeister K, Nestler U, Paradowska A, et al. PTPIP51, a positive modulator of the MAPK\/Erk pathway, is upregulated in glioblastoma and interacts with 14-3-3\u03b2 and PTP1B in situ. Histol Histopathol. 2011;26:1531\u201343.","journal-title":"Histol Histopathol"},{"key":"3795_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.120293","volume":"297","author":"M He","year":"2022","unstructured":"He M, Wang X, Chen W, Zhang J, Xiong Y, Cao L, et al. PTPIP51 inhibits non-small-cell lung cancer by promoting PTEN-mediated EGFR degradation. Life Sci. 2022;297:120293.","journal-title":"Life Sci"},{"key":"3795_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/01.RES.73.1.98","volume":"73","author":"P Sil","year":"1993","unstructured":"Sil P, Misono K, Sen S. Myotrophin in human cardiomyopathic heart. Circ Res. 1993;73:98\u2013108.","journal-title":"Circ Res"},{"key":"3795_CR45","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0735-1097(03)00755-1","volume":"42","author":"RJ O\u2019Brien","year":"2003","unstructured":"O\u2019Brien RJ, Loke I, Davies JE, Squire IB, Ng LL. Myotrophin in human heart failure. J Am Coll Cardiol. 2003;42:719\u201325.","journal-title":"J Am Coll Cardiol"},{"key":"3795_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003495-200464010-00007","volume":"64","author":"NA Reynolds","year":"2004","unstructured":"Reynolds NA, Wagstaff AJ. Cetuximab: in the treatment of metastatic colorectal cancer. Drugs. 2004;64:109\u201318.","journal-title":"Drugs"},{"key":"3795_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, et al. EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer. Cancer Discov. 2020;10:1129\u201339.","journal-title":"Cancer Discov"},{"key":"3795_CR48","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1158\/0008-5472.CAN-14-0013","volume":"74","author":"D Mouradov","year":"2014","unstructured":"Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 2014;74:3238\u201347.","journal-title":"Cancer Res"},{"key":"3795_CR49","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-17-1452","volume":"8","author":"Y Gao","year":"2018","unstructured":"Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, et al. Allele-specific mechanisms of activation of mek1 mutants determine their properties. Cancer Discov. 2018;8:648\u201361.","journal-title":"Cancer Discov"},{"key":"3795_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nmeth.1506","volume":"7","author":"S Bandyopadhyay","year":"2010","unstructured":"Bandyopadhyay S, Chiang CY, Srivastava J, Gersten M, White S, Bell R, et al. A human MAP kinase interactome. Nat Methods. 2010;7:801\u20135.","journal-title":"Nat Methods"},{"key":"3795_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.semcdb.2011.09.002","volume":"23","author":"IA Prior","year":"2012","unstructured":"Prior IA, Hancock JF. Ras trafficking, localization and compartmentalized signalling. Semin Cell Dev Biol. 2012;23:145\u201353.","journal-title":"Semin Cell Dev Biol"},{"key":"3795_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.116138","volume":"450","author":"L Wu","year":"2022","unstructured":"Wu L, Wang Z, He X, Jiang Y, Pan R, Chen S, et al. GJA1 reverses arsenic-induced EMT via modulating MAPK\/ERK signaling pathway. Toxicol Appl Pharm. 2022;450:116138.","journal-title":"Toxicol Appl Pharm"},{"key":"3795_CR53","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/1759-7714.15196","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Pan B, Zhang F, Jia X, Zhu X, Tong X, et al. TPI1 promotes MAPK\/ERK-induced EMT, cell migration and invasion in lung adenocarcinoma. Thorac Cancer. 2024;15:327\u201338.","journal-title":"Thorac Cancer"},{"key":"3795_CR54","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41417-020-0206-7","volume":"28","author":"L Huang","year":"2021","unstructured":"Huang L, Chen S, Fan H, Ji D, Chen C, Sheng W. GINS2 promotes EMT in pancreatic cancer via specifically stimulating ERK\/MAPK signaling. Cancer Gene Ther. 2021;28:839\u201349.","journal-title":"Cancer Gene Ther"},{"key":"3795_CR55","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.4161\/cc.21670","volume":"11","author":"H Cheng","year":"2012","unstructured":"Cheng H, Hong B, Zhou L, Allen JE, Tai G, Humphreys R, et al. Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle. 2012;11:3312\u201323.","journal-title":"Cell Cycle"},{"key":"3795_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/gutjnl-2013-306584","volume":"64","author":"J Qian","year":"2015","unstructured":"Qian J, Kong X, Deng N, Tan P, Chen H, Wang J, et al. OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer. Gut. 2015;64:37\u201348.","journal-title":"Gut"},{"key":"3795_CR57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100\u20133.","journal-title":"Nature"},{"key":"3795_CR58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44\u201354.","journal-title":"N Engl J Med"},{"key":"3795_CR59","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1128\/MCB.25.18.7940-7952.2005","volume":"25","author":"M Roy","year":"2005","unstructured":"Roy M, Li Z, Sacks DB. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling. Mol Cell Biol. 2005;25:7940\u201352.","journal-title":"Mol Cell Biol"},{"key":"3795_CR60","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s13402-021-00610-3","volume":"44","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang W, Chen L, Chen W, Xu S, Tang L, et al. The ATO\/miRNA-885-5p\/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma. Cell Oncol. 2021;44:907\u201316.","journal-title":"Cell Oncol"},{"key":"3795_CR61","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3892\/ol.2021.12709","volume":"21","author":"F Klupp","year":"2021","unstructured":"Klupp F, Sass M, Bergmann F, Khajeh E, Ghamarnejad O, Hassenpflug M, et al. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer. Oncol Lett. 2021;21:448.","journal-title":"Oncol Lett"},{"key":"3795_CR62","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000030116","volume":"21","author":"I Porebska","year":"2000","unstructured":"Porebska I, Harlozi\u0144ska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERBB2, ERBB3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 2000;21:105\u201315.","journal-title":"Tumour Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03795-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:02:26Z","timestamp":1780005746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":62,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,6,19]]}},"alternative-id":["3795"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03795-9","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"12 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}